Schizophrenia, tardive dyskinesia and essential fatty acids

Schizophrenia Research

Volumn 20, Issue 3, 1996, Pages 287-294

  Vaddadi, Krishna S ^a   Gilleard, Christopher J ^b   Soosai, Eileen ^a   Polonowita, A K ^c   Gibson, Robert A ^d   Burrows, Graham D ^e  

^a MAROONDAH HOSPITAL   (Australia)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c Western Suburbs Psychiatric Clinic   (Australia)

^d FLINDERS MEDICAL CENTRE   (Australia)

^e AUSTIN HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DIHOMO GAMMA LINOLEIC ACID; FATTY ACID; LINOLEIC ACID; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; ERYTHROCYTE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; PRIORITY JOURNAL; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

EID: 0030570528     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/0920-9964(95)00095-X     Document Type: Article

References (28)

1. Abdullah YH, Hamadah K (1975) Effect of ADP on PGE formation in blood platelets from patients with depression, mania and schizophrenia. Br J Psychiatry 127, 591-595.
2. American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition (Revised). A.P.A., Washington, DC.
3. Cleland LG, Gibson RA, Newman M, French JK (1990) The effect of dietary fish oil supplementation upon the content of dihomogammalinolenic acid in human plasma phospholipids. Prostaglandins, Leukotrienes Fatty Acids 40, 9-12.
4. Clinical Handbook of Psychotropic Drugs (1989) Bezchlibnyk-Butler KZ, Jeffries JJ (eds) Clarke Institute of Psychiatry, Toronto, Canada. Hans Huber Publishers, Toronto.
5. Crawford MA, Hassam AG, Stevans PA (1982) Essential fatty acid requirements in pregnancy and lactation with special reference to brain development. Prog Lipid Res 20, 31-40.
6. Davidson B, Kurstiens NP, Patton J, Cantrill RC (1988) Essential fatty acids modulate apomorphine activity at receptors in cat caudate slices. Eur J Pharmacol 149, 317-322.
7. Glen AIM, Glen EMT, Horrobin DF, Vaddadi KS, Spellman-Fisher N, Ellis K, Skinner FS (1994) A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases. Schizophr Res 12, 53-61.
8. Hitzemann RJ, Garver DI (1982) Membrane abnormalities in schizophrenia. Psychopharmacol Bull 18, 190-192.
9. Honstra G (1992) Essential fatty acids, pregnancy and pregnancy complications: A roundtable discussion. In: Sinclair A, Gibson R (eds) Essential Fatty Acids and Eicosanoids: Invited papers from the Third International Conference on Essential Fatty Acids and Eicasonoids. American Oil Chemists' Society, Champaign, IL, pp. 177-182.
10. Horrobin DF (1977) Schizophrenia as a prostaglandin deficiency disease. Lancet i, 1936-1937.
11. Horrobin DF (1990) Essential fatty acids, psychiatric disorders and neuropathies. In: Horrobin DF (ed) Omega 6 Essential Fatty Acids: Pathophysiology and Roles in Clinical Medicine. Alan Liss, New York, pp. 305-319.
12. Horrobin DF, Manku MS, Morse-Fisher N, Vaddadi KS, Courtney P, Glen AIM, Glen E, Spellman M, Bates C (1989) Essential fatty acids in plasma phospholipids in schizophrenic. Biol Psychiatry 25, 562-568.
13. Horrobin DF, Manku MS, Hillman H, Glen AI, Glen M (1991) Fatty acid levels in the brain of schizophrenics and normal controls. Biol Psychiatry 30, 795-805.
14. Horrobin DF, Glen AIM, Vaddadi KS (1994) The membrane hypothesis of schizophrenia. Schizophr Res 13, 195-207.
15. Houtia NE, Maziere JC, Maziere C, Auclair M (1988) Phenothiazines inhibit cholesteryl ester formation in J774 monocyte like cells. J Clin Chem Clin Biochem 26, 673-678.
16. Kaiya H, Horrobin DF, Manku MS, Morse-Fisher N (1991) Essential and other fatty acids in plasma in schizophrenics and normal individuals from Japan. Biol Psychiatry 30, 357-362.
17. Kanof PD, Davidson M, Johns CA, Mohs RC, Davis KL (1987) Clinical correlates of platelets prostaglandins receptor subsensitivity in schizophrenia. Am J Psychiatry 44, 1556-1560.
18. Nohria V, Vaddadi KS (1982) Tardive dyskinesia and essential fatty acids: An animal model study. In: Horrobin DF (ed) Clinical Uses of Essential Fatty Acids. Montreal, Eden Press, pp. 199-204.
19. Pall HS, Williams AC, Blake DR, Lunec J (1987) Evidence of enhanced lipid peroxidation in the cerebrospinal fluid of patients taking phenothiazines. Lancet i, 596-599.
20. Schooler NR, Kane JM (1982) Research diagnostic criteria for tardive dyskinesia. Arch Gene Psychiatry 39, 486-487.
21. Sengupta N, Datta SC, Sengupta D (1981) Platelet and erythrocyte membrane lipid and phospholipid pattern in different types of mental patients. Biochem Med 25, 267-275.
22. Simpson GH, Lee JH, Zovbok B, Gardos G (1979) A rating scale for tardive dyskinesia. Psychopharmacology 64, 171-179.
23. Vaddadi KS, Gilleard CJ, Mindham RHS, Butler R (1986) A controlled trial of prostaglandin E1 treatment of schizophrenia. Psychopharmacology 88, 362-367
24. Vaddadi KS, Courtney P, Gilleard CJ, Manku MS, Horrobin DF (1989) A double blind trial of essential fatty acid supplementation in patients with tardive dyskinesia. Psychiatry Res 27, 313-323.
25. Vaddadi KS, Gilleard CJ (1990) Essential fatty acids, tardive dyskinesia and schizophrenia. In: Horrobin DF (ed) Omega-6 Essential Fatty Acids: Pathophysiology and Roles in Clinical Medicine. New York, Alan R Liss, pp. 333-343.
26. Vaddadi KS (1992) Essential fatty acids and alpha-tocopherol supplementation in tardive dyskinesia. In: Packer L-, Prilipko L, Christen Y, (eds) Free Radicals in the Brain: Aging, Neurological and Mental Disorders. Berlin, Springer-Verlag, pp. 74-90.
27. Van Kammen DP, Yao JK, Goetz K (1989) Polyunsaturated fatty acids, prostaglandins and schizophrenia. Ann NY Acad Sci 559, 411-423.
28. Wiles DH, Kolakawski AT, McNeilly AS, Mandlebrite BM, Gelder MG (1976) Significance of plasma chlorpromazine levels 1. Plasma levels of the drug and some of its metabolises and prolactin during acute treatment. Psychol Med 6, 407-415.